India's Bharat Serum and Vaccines to Repurpose Sepsis Drug for COVID-19, an Industrial Info Market Brief
Indian vaccine-maker Bharat Serums and Vaccines Limited (BSVL) said it has received approval from the Drug Controller General of India (DCGI) to conduct the Phase III clinical trial of Sepsis drug Ulinastatin on COVID-19 patients showing mild-to-moderate acute respiratory distress symptoms.
Ulinastatin is used in India, China and Japan in the treatment of severe sepsis and other critical clinical conditions such as acute pancreatitis. Clinical trials to evaluate efficacy of the drug are likely to commence soon in six hospitals across India, enrolling 120 patients. Results are expected to be available by December 2020.
